Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2006

Open Access 01-12-2006 | Research

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients

Authors: Isabella Laura Simone, Antonia Ceccarelli, Carla Tortorella, Alessandra Bellacosa, Fabio Pellegrini, Immacolata Plasmati, Maria Fara De Caro, Mariangela Lopez, Francesco Girolamo, Paolo Livrea

Published in: Health and Quality of Life Outcomes | Issue 1/2006

Login to get access

Abstract

Background

Interferon-beta (IFN-β) shows beneficial effect on the course of multiple sclerosis (MS), nevertheless its route and frequency of administration and side effects might impact negatively the quality of life (QoL) of MS patients. The objective of this study was to evaluate the influence of IFN-β on QoL in MS patients.

Methods

Seventy-seven disease modifying treatment (DMT) free and 41 IFN-β treated MS patients were evaluated. QoL, assessed by MSQoL-54, was related to IFN-β treatment and to clinical and demographic parameters at baseline and after two years. Multivariate hierarchical linear model for repeated measurements was used.

Results

Treated patients showed a younger age, a lower disease duration and a higher relapse rate in the two years preceding study entry. At inclusion time treated and untreated patients did not differ in relapse rate, expanded disability status scale (EDSS), fatigue, depression, physical and mental QoL. IFN-β did not influence QoL at inclusion time, but when QoL was evaluated after two years, treatment negatively affected mental QoL. Depression and fatigue negatively influenced physical and mental QoL both at baseline and after two years. EDSS correlated with a poor physical QoL only at baseline.

Conclusion

IFN-β had a negative impact on QoL over the time in MS patients, influencing mainly mental QoL. The impairment of QoL in MS was strongly associated with increasing fatigue and depression, whereas clinical disability had a minor unfavourable role.
Literature
1.
Nortvedt MW, Riise T, Myhr KM, Nyland HI: Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999, 53: 1098–1103.PubMedCrossRef
2.
The Canadian Burden of Illness Study Group: Burden of illness of multiple sclerosis. II. Quality of life. Can J Neurol Sci 1998, 25: 31–38.
3.
Nortvedt MW, Riise T: The use of quality of life measures in multiple sclerosis research. Mult Scler 2003, 9: 63–72. 10.1191/1352458503ms871oaPubMedCrossRef
4.
Kurtzke JF: Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983, 33: 1444–1452.PubMedCrossRef
5.
Shawaryn MA, Schiaffino KM, LaRocca NG, Johnston MV: Determinants of health-related quality of life in multiple sclerosis: the role of illness intrusiveness. Mult Scler 2002, 8: 310–318. 10.1191/1352458502ms808oaPubMedCrossRef
6.
Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L: Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler 2001, 7: 340–344. 10.1191/135245801681138059PubMedCrossRef
7.
Zivadinov R, Zorzon M, Tommasi MA, Nasuelli D, Bernardi M, Monti-Bragadin L, Cazzato G: A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci 2003, 216: 113–118. 10.1016/S0022-510X(03)00225-9PubMedCrossRef
8.
Patti F, Capocardo M, Palermo F, Ciancio MR, Lopes R, Restivo D, Reggio A: Health-related quality of life and depression in an Italian sample of multiple sclerosis patients. J Neurol Sci 2003, 211: 55–62.PubMedCrossRef
9.
Janssen ACJW, van Doorn PA, de Boer JB, Kalkers NF, van der Mechè FCA, Passchier J: Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis. Mult Scler 2003, 9: 397–403. 10.1191/1352458503ms930oaCrossRef
10.
Lobentanz IS, Asenbaum S, Vass K, Sauter C, Klosch G, Kollegger H, Ristoferitsch W, Zeitlhofer J: Factors influencing quality of life in multiple sclerosis patients, depressive mood, fatigue and sleep quality. Acta Neurol Scand 2004, 110: 6–13. 10.1111/j.1600-0404.2004.00257.xPubMedCrossRef
11.
Benedict RHB, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, Weinstock-Guttman B: Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci 2005, 231: 29–34. 10.1016/j.jns.2004.12.009PubMedCrossRef
12.
Mitchell AJ, Benito-León J, Moralez-Gonzales JM, Rivera-Navarro J: Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 2005, 4: 556–566. 10.1016/S1474-4422(05)70166-6PubMedCrossRef
13.
Rice GP, Oger J, Duquette P, Francis GS, Belanger M, Laplante S, Grenier JF: Treatment with interferon beta-1b improves quality of life in multiple sclerosis. Can J Neurol Sci 1999, 26: 276–282.PubMedCrossRef
14.
Arnoulds JHA, Kilestein J, Pfennings L, Jelles B, Uitdehaag BMJ, Polman CH: Quality of life during the first 6 months of interferon-β treatment in patients with MS. Mult Scler 2000, 6: 338–342. 10.1191/135245800678827932
15.
Nortvedt MW, Riise T, Myhr KM, Nyland HI, Hanestad BR: Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a. Mult Scler 1999, 5: 317–322. 10.1191/135245899678846339PubMedCrossRef
16.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS: Recommended diagnostic criteria for multiple sclerosis: guidelines from International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50: 21–127. 10.1002/ana.1032CrossRef
17.
Vickrey BG, Hays RD, Harooni R, Meyers LW, Elfison GW: A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995, 4: 187–206. 10.1007/BF02260859PubMedCrossRef
18.
Solari A, Filippini G, Mendozzi L, Ghezzi A, Cifani S, Barbieri E, Baldini S, Salmeggi A, La Mantia L, Farinotti M, Caputo D, Mosconi P: Validation of italian multiple sclerosis quality of life 54 questionnaire. J Neurol Neurosurg Psychiatry 1999, 67: 158–162.PubMedCentralPubMedCrossRef
19.
Ware JE, Sherbourne CD: A 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992, 30: 473–483. 10.1097/00005650-199206000-00002PubMedCrossRef
20.
Krupp LB, La Rocca NG, Muir-Nash J, Steinberg AD: The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46: 1121–1124.PubMedCrossRef
21.
Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh JK: An inventory for measuring depression. Arch Gen Psychiatry 1961, 4: 561–571.PubMedCrossRef
22.
Measso G, Cavarzeran F, Zappalà G, Lebowitz BD, Crook TH, Pirizzolo F: The mini-mental state examination: normative study of an Italian random sample. Dev Neuropsychol 1993, 9: 77–85.CrossRef
23.
Singer JD, Willett JB: Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York: Oxford University Press; 2003.CrossRef
24.
Diggle PJ, Liang KY, Zeger SL: Analysis of Longitudinal Data. Oxford: Oxford University Press; 1994.
25.
Gottberg K, Garduf A, Fredrikson S: Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects. Mult Scler 2000, 6: 349–354. 10.1191/135245800678827978PubMedCrossRef
26.
Freeman JA, Thompson AJ, Fitzpatrick R, Hutchinson M, Miltenburger C, Beckmann K, Dahlke F, Kappos L, Polman C, Pozzilli C, European Study Group Interferon-beta1b in Secondary Progressive MS: Interferon-β 1b in the treatment of secondary progressive MS. Impact on quality of life. Neurology 2001, 57: 1870–1875.PubMedCrossRef
27.
Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN, IMPACT Investigators: Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology 2002, 59: 679–687.PubMedCrossRef
28.
Isaksson AK, Ahlström G, Gunnarsson LG: Quality of life and impairment in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005, 76: 64–69. 10.1136/jnnp.2003.029660PubMedCentralPubMedCrossRef
29.
Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, Rodriguez M: Quality of life is favorable for must patients with multiple sclerosis. Arch Neurol 2000, 61: 679–686. 10.1001/archneur.61.5.679CrossRef
30.
Solari A, Ferrari G, Radice D: A longitudinal survey of self-assessed health trends in a community cohort of people with multiple sclerosis and their significant others. J Neurol Sci 2006, 243: 13–20. 10.1016/j.jns.2005.11.005PubMedCrossRef
31.
Vermersch P, de Seze J, Delisse B, Lemaire S, Stojkovic T: Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatmen. Mult Scler 2002, 8: 377–381. 10.1191/1352458502ms826oaPubMedCrossRef
32.
Janardhan V, Baskshi R: Quality of life in patients with multiple sclerosis: The impact of fatigue and depression. J Neurol Sci 2002, 205: 51–58. 10.1016/S0022-510X(02)00312-XPubMedCrossRef
33.
Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ: A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry 2005, 76: 58–63. 10.1136/jnnp.2003.017897PubMedCentralPubMedCrossRef
Metadata
Title
Influence of Interferon beta treatment on quality of life in multiple sclerosis patients
Authors
Isabella Laura Simone
Antonia Ceccarelli
Carla Tortorella
Alessandra Bellacosa
Fabio Pellegrini
Immacolata Plasmati
Maria Fara De Caro
Mariangela Lopez
Francesco Girolamo
Paolo Livrea
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2006
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-4-96

Other articles of this Issue 1/2006

Health and Quality of Life Outcomes 1/2006 Go to the issue

Research

Quality of life and hormone use: new validation results of MRS scale

Research

Health-related quality of life following a clinical weight loss intervention among overweight and obese adults: intervention and 24 month follow-up effects

Research

Physician-estimated disease severity in patients with chronic heart or lung disease: a cross-sectional analysis

Research

Development of the Well-being questionnaire short-form in Japanese: the W-BQ12

Research

Interest in healthy living outweighs presumed cultural norms for obesity for Ghanaian women

Research

Impact, distress and HRQoL among Malaysian men and women with a mobility impairment